Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients ; volume:17 ; number:1 ; day:16 ; month:3 ; year:2017 ; pages:1-7 ; date:12.2017
BMC infectious diseases ; 17, Heft 1 (16.3.2017), 1-7, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Maggiolo, Franco
- Beteiligte Personen und Organisationen
-
Gulminetti, Roberto
Pagnucco, Layla
Digaetano, Margherita
Benatti, Simone
Valenti, Daniela
Callegaro, Annapaola
Ripamonti, Diego
Mussini, Cristina
SpringerLink (Online service)
- DOI
-
10.1186/s12879-017-2311-2
- URN
-
urn:nbn:de:1111-201704062889
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maggiolo, Franco
- Gulminetti, Roberto
- Pagnucco, Layla
- Digaetano, Margherita
- Benatti, Simone
- Valenti, Daniela
- Callegaro, Annapaola
- Ripamonti, Diego
- Mussini, Cristina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
HIV lamivudine resistance mutations in HBV co-infected Romanian patients
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
HIV lamivudine resistance mutations in HBV co-infected Romanian patients
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
HIV lamivudine resistance mutations in HBV co-infected Romanian patients